Professional Documents
Culture Documents
doi: 10.1111/1346-8138.12687
ORIGINAL ARTICLE
Department of Dermatology, School of Medicine, Pusan National University, 2Biomedical Research Institute, Pusan National University
Hospital, and 3Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital,
Busan, Korea
ABSTRACT
Doxycycline is the standard systemic treatment for rosacea. Recently, there have been a few reports on b-adrenergic blockers such as nadolol, carvedilol and propranolol for suppressing flushing reactions in rosacea. To our
knowledge, there are no comparative studies of propranolol and doxycycline, and combination therapy using
both. The aim of this study was to investigate and compare the efficacy and safety of monotherapy of propranolol, doxycycline and combination therapy. A total of 78 patients who visited Pusan National University Hospital
and were diagnosed with rosacea were included in this study. Among them, 28 patients were in the propranolol
group, 22 the doxycycline group and 28 the combination group. We investigated the patient global assessment
(PGA), investigator global assessment (IGA), assessment of rosacea clinical score (ARCS) and adverse effects.
Improvement in PGA and IGA scores from baseline was noted in all groups, and the combination therapy was
found to be the most effective during the entire period, but this was statistically insignificant. The reduction rate
of ARCS during the treatment period was also highest in the combination group (57.4%), followed by the doxycycline group (52.2%) and the propranolol group (51.0%). Three patients in the combination group had mild and
transient gastrointestinal disturbances but there was no significant difference from the other groups. We conclude that the combination therapy of doxycycline and propranolol is effective and safe treatment for rosacea and
successful for reducing both flushing and papulation in particular.
Key words:
INTRODUCTION
Rosacea is a common chronic dermatological condition characterized by recurrent episodes of exacerbation and remission.
It usually affects individuals between the ages of 30 and
50 years and women are more affected than men.1,2 Classification of rosacea includes erythematotelangiectatic (ETR), papulopustular (PPR), phymatous and ocular subtypes.35 ETR is
characterized by flushing and persistent central facial erythema
and PPR presents with persistent facial erythema and transient
papules or pustules, or both, in a central facial distribution.3
The etiology of rosacea is still unknown and this condition
has led to a therapeutic challenge. Although there is no curative treatment for rosacea, tetracycline compounds have been
the mainstay therapy and among them, tetracycline and doxycycline are the standard systemic therapy of rosacea. Doxycycline shows anti-inflammatory effects and antioxidant
properties. It exhibits superior pharmacokinetic advantages
and lesser toxicity than tetracycline, so it is widely used for
rosacea.6
METHODS
Patients
Rosacea patients aged above 18 years who visited the outpatient clinic of the Department Of Dermatology at Pusan
National University Hospital from August 2008 to August 2012
were enrolled. The exclusion criteria were patients who had
been treated with topical and systemic medications which can
Correspondence: Hyun-Chang Ko, M.D., Department of Dermatology, School of Medicine, Pusan National University, Geumoh-ro 20,
Mulgeum-eup, Yangsan-si, Busan, Gyeongsangnam-do 626-770, Korea. Email: hcko@pusan.ac.kr
Received 23 January 2014; accepted 29 September 2014.
64
affect the symptoms of rosacea (e.g. other antibiotics, isotretinoin, corticosteroid, cyclosporin) or with laser that targeted the
vasculature, such as flash pumped pulsed dye laser and
intense pulsed light, for the previous year. For the doxycycline
group, pregnant or lactating women and patients with accompanying chronic renal failure, hepatic failure and myasthenia
gravis were excluded. For the propranolol group, patients with
bronchial asthma, hypotension, bradycardia, atrioventricular
block, sinoatrial block and congestive heart failure were
excluded.
Methods
The study protocol was approved by the Pusan National University Hospital institutional review board.
At their first visit, the patients age, sex and disease duration
were recorded and the severity of the rosacea was assessed.
Subtypes of rosacea (ETR and PPR), distribution, aggravating
factors and symptomatology were also checked.
The global change assessment in the rosacea condition,
as assessed by the patient global assessment (PGA) and
investigator global assessment (IGA), was compared with
Doxycycline
group (n = 15)
Combination
group (n = 26)
Total
(n = 63)
47.4 11.8
4:11
4:11
25.3 30.1
2.0 1.7
48.4 12.6
4:9
9:17
29.2 32.6
2.0 1.0
50.6 12.8
16:47
32:31
29.7 37.0
2.3 1.8
1
14
7
5
2
2
(6.7)
(93.3)
(46.7)
(33.3)
(13.3)
(13.3)
16
21
15
16
14
3
(61.5)
(80.8)
(57.7)
(61.5)
(53.8)
(11.5)
19
55
24
24
20
8
(30.2)
(87.3)
(38.1)
(38.1)
(31.7)
(12.7)
8
9
6
3
3
0
0
(53.3)
(60.0)
(40.0)
(20.0)
(20.0)
13
13
6
6
3
4
0
(50.0)
(50.0)
(23.1)
(23.1)
(11.5)
(15.4)
43
30
18
14
10
7
1
(68.3)
(47.6)
(28.6)
(22.2)
(15.9)
(11.1)
(1.6)
21 (80.8)
3 (11.5)
4 (15.4)
0
51
8
10
1
(81.0)
(12.7)
(15.9)
(1.6)
12 (80.0)
3 (20.0)
1 (6.7)
0
(a)
(b)
Figure 1. (a) Mean physician global assessment and (b) investigator global assessment scores of rosacea patients through
12 weeks.
65
4 weeks
8 weeks
12 weeks
P*
2.4
2.1
1.7
1.9
0.5
0.4
0.5
0.4
1.7
1.8
1.6
1.7
0.5
0.6
0.5
0.5
1.3
1.4
1.6
1.4
0.6
0.6
0.5
0.7
0.7
1.1
1.5
1.2
0.6
0.6
0.5
0.7
<0.05
<0.05
0.23
<0.05
2.1
2.4
2.5
2.4
0.4
0.5
0.5
0.6
2.0
1.9
1.6
1.9
0.4
0.5
0.6
0.5
1.7
1.7
1.3
1.8
0.5
0.5
0.8
0.4
1.5
1.2
0.8
1.6
0.5
0.4
0.7
0.5
<0.05
<0.05
<0.05
<0.05
2.2
2.1
2.3
1.9
0.5
0.3
0.5
0.4
1.5
1.7
1.5
1.7
0.6
0.5
0.6
0.5
1.3
1.5
1.1
1.5
0.7
0.5
0.6
0.6
0.7
1.0
0.5
1.2
0.5
0.6
0.5
0.6
<0.05
<0.05
<0.05
<0.05
baseline and scored on a 7-point scale, with +3 being markedly improved, +2 moderately improved, +1 mildly improved,
0 unchanged, 1 mildly worse, 2 moderately worse and
3 markedly worse.9 The assessment of rosacea clinical
score (ARCS) was also checked.4 PGA and IGA were
checked at weeks 2, 4, 8 and 12 and ARCS at baseline and
at weeks 4, 8 and 12. Laboratory tests were done for complete blood cell count, liver and renal functions, and urinalysis before and during the treatment.
The patients with rosacea were divided into three groups:
28 patients treated with propranolol 10 mg three times a day
(propranolol group); 22 patients treated with doxycycline
100 mg two times a day (doxycycline group); and 28 patients
treated with propranolol 10 mg three times a day and doxycycline 100 mg two times a day (combination group).
Statistical analysis
The KruskalWallis test was performed to evaluate differences
between the three groups using the PASW for Windows (IBM,
Armonk, NY, USA). Students two-sample t-test was performed
to estimate the differences of the score for the primary features
of ARCS between baseline and after 12 weeks of treatment.
Statistical significance was defined as P < 0.05.
RESULTS
Of the 78 subjects enrolled, 63 completed the study. In the
propranolol group, 78.6% (22/28) of patients completed the
study. Among the six patients who dropped out, other systemic agents were added in the treatment of five patients
(three with doxycycline, one with minocycline, one with isotretinoin) and one patient decided to change to doxycycline
because of the unsatisfactory effects of the propranolol on the
erythema and papules. In the doxycycline group, 68.2% (15/
22) of the patients completed the study. Three patients added
propranolol, one patient added laser therapy, and three
patients changed to propranolol because of the unsatisfactory
66
4 weeks
8 weeks
12 weeks
Propranolol
group (%)
Doxycycline
group (%)
Combination
group (%)
14.6
29.2
42.4
20.7
29.6
43.1
24.5
36.4
60.0
0.037
0.436
0.003
(a)
(b)
(c)
Figure 3. Serial changes of rosacea patients after 12 weeks of treatment. (a) A 72-year-old woman (erythematotelangiectatic) in the
propranolol group. (b) A 41-year-old man (papulopustular) in the doxycycline group. (c) A 55-year-old woman (papulopustular) in the
combination group.
67
Adverse effect
Total (%)
2 (9.0): dyspepsia (n = 1)
headache (n = 1)
3 (20.0): gastrointestinal
disturbance
3 (11.5): gastrointestinal
disturbance
8 (12.7)
DISCUSSION
Rosacea is a chronic inflammatory skin disease and yet the
underlying pathophysiology is not entirely known.10 It is characterized by persistent erythema, telangiectasia, papules and
even pustules on the face.11 Various causes have been found
to act as aggravation factors of rosacea, such as emotional
change, heat, exercise, bathing, alcohol, cold and sun exposure, and it is difficult to avoid all provocative stimuli.12,13 Thus,
the therapeutic approach of rosacea depends more on the
clinical subtype than a known etiology.14
Treatment for rosacea includes topical anti-inflammatory
agents, topical or systemic antibacterials, retinoids and laser
therapy.14 Oral tetracycline, particularly tetracycline and doxycycline, have been the mainstay of treatment of rosacea for a
long time. They are especially effective in treating PPR but also
ETR through inhibition of leukocyte-derived matrix-degrading
metalloproteinases.15,16 Flushing usually does not respond to
conventional rosacea treatment. Therefore, treatment of ETR
with severe flushing is challenging although some successes
with beta-blockers such as nadolol, carvedilol and propranolol
have been reported.7,17 Propranolol has not demonstrated
objective evidence for direct effects on cutaneous blood vessels in flushing, but a previous study reported that 88.9% (8/9)
of patients showed improvement of their symptoms and had
fewer flushing episodes while taking propranolol.7 The mechanism
68
CONFLICT OF INTEREST:
interest to declare.
REFERENCES
1 Powell FC. Clinical practice. Rosacea. N Engl J Med 2005; 352:
793803.
2 Berg M, Liden S. An epidemiological study of rosacea. Acta Derm
Venereol 1989; 69: 419423.
3 Wilkin J, Dahl M, Detmar M et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on
the classification and staging of rosacea. J Am Acad Dermatol
2002; 46: 584587.
4 Wilkin J, Dahl M, Detmar M et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on
the classification and staging of rosacea. J Am Acad Dermatol
2004; 50: 907912.
5 Lee JY. Rosacea: clinical aspects, pathogenesis and treatment.
Dermatol Sinica 2005; 23: 121130.
nchez JL, Rivera A. Safety and efficacy of
6 Valentn S, Morales A, Sa
doxycycline in the treatment of rosacea. Clin Cosmet Investig
Dermatol 2009; 2: 129140.
7 Craige H, Cohen JB. Symptomatic treatment of idiopathic and rosacea associated cutaneous flushing with propranolol. J Am Acad
Dermatol 2005; 53: 881884.
8 Hsu CC, Lee JY. Carvedilol for the treatment of refractory facial
flushing and persistent erythema of rosacea. Arch Dermatol 2011;
147: 12581260.
9 Draelos ZD, Ertel K, Berge C. Niacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea.
Cutis 2005; 76: 135141.
10 Conde JF, Yelverton CB, Balkrishnan R et al. Managing rosacea: a
review of the use of metronidazole alone and in combination with
oral antibiotics. J Drugs Dermatol 2007; 6: 495498.
11 Marks R. The enigma of rosacea. J Dermatolog Treat 2007; 18:
326328.
12 Lee SY, Choi JH, Sung KJ, Moon KC, Koh JK. A clinical study of
112 patients with rosacea. Korean J Dermatol 2001; 39: 636642.
s E et al. The role of free oxygen radicals in
13 Oztas MO, Balk M, Ogu
the aetiopathogenesis of rosacea. Clin Exp Dermatol 2003; 28: 188
192.
14 Alikhan A, Kurek L, Feldman SR. The role of tetracyclines in rosacea. Am J Clin Dermatol 2010; 11: 7987.
15 Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties
and their clinical implications. J Am Acad Dermatol 2006; 54: 258
265.
16 Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin 2007; 25: 133135.
17 Hsu CC, Lee JY. Pronounced facial flushing and persistent
erythema of rosacea effectively treated by carvedilol, a nonselective b-adrenergic blocker. J Am Acad Dermatol 2012; 67: 491
493.
18 Mak IT, Weglicki WB. Potent antioxidant properties of 4-hydroxylpropranolol. J Pharmacol Exp Ther 2004; 308: 8590.
19 Jones D. Reactive oxygen species and rosacea. Cutis 2004; 74
(Suppl): 1720, 324.
20 Wise RD. Submicrobial doxycycline and rosacea. Comp Ther 2007;
33: 7881.
21 Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol 1994; 130: 319324.
69